Related references
Note: Only part of the references are listed.The therapeutic potential of targeting tryptophan catabolism in cancer
Christiane A. Opitz et al.
BRITISH JOURNAL OF CANCER (2020)
ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer
Guru Sonpavde et al.
FUTURE ONCOLOGY (2020)
Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma Cells and in Intratumoral Pericytes of Most Cancers
Delia Hoffmann et al.
CANCER IMMUNOLOGY RESEARCH (2020)
A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma
David A. Reardon et al.
INVESTIGATIONAL NEW DRUGS (2020)
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Kyung Hae Jung et al.
CLINICAL CANCER RESEARCH (2019)
Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond
Alexander J. Muller et al.
SEMINARS IN IMMUNOPATHOLOGY (2019)
BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC).
Jason J. Luke et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Michael Platten et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Mesenchymal stem cells inhibit T-cell function through conserved induction of cellular stress
Adam G. Laing et al.
PLOS ONE (2019)
Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1)
Ute F. Rohrig et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina Long et al.
LANCET ONCOLOGY (2019)
Echoes of a failure: what lessons can we learn?
Vernon K. Sondak et al.
LANCET ONCOLOGY (2019)
IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1
Erik A. Dill et al.
MODERN PATHOLOGY (2018)
Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form
Micah T. Nelp et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
Tara C. Mitchell et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids
Sarah J. Hill et al.
CANCER DISCOVERY (2018)
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (ID01) Inhibitor for Immunooncology
Eddy W. Yue et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines
Marion A. A. Libouban et al.
ONCOTARGET (2017)
Discovery of IDO1 Inhibitors: From Bench to Bedside
George C. Prendergast et al.
CANCER RESEARCH (2017)
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2017)
Isolation of Mononuclear Cell Populations from Ovarian Carcinoma Ascites
Christina Wefers et al.
BIO-PROTOCOL (2017)
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
Rikke B. Holmgaard et al.
CELL REPORTS (2015)
Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
Ivan Theate et al.
CANCER IMMUNOLOGY RESEARCH (2015)
flowFit: a Bioconductor package to estimate proliferation in cell-tracking dye studies
Davide Rambaldi et al.
BIOINFORMATICS (2014)
Persistent infectious diseases say - IDO. Role of indoleamine-2,3-dioxygenase in disease pathogenesis and implications for therapy
Heidi Barth et al.
CRITICAL REVIEWS IN MICROBIOLOGY (2014)
High-Throughput Fluorescence-Based Screening Assays for Tryptophan-Catabolizing Enzymes
Nicole Seegers et al.
JOURNAL OF BIOMOLECULAR SCREENING (2014)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Immunological and Nonimmunological Effects of Indoleamine 2,3-Dioxygenase on Breast Tumor Growth and Spontaneous Metastasis Formation
Vera Levina et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
Luc Pilotte et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
Jessica Godin-Ethier et al.
CLINICAL CANCER RESEARCH (2011)
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Christiane A. Opitz et al.
NATURE (2011)
Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors
Holly K. Koblish et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma
Tomoko Inaba et al.
GYNECOLOGIC ONCOLOGY (2009)
A fluorescence-based assay for indoleamine 2,3-dioxygenase
A Matin et al.
ANALYTICAL BIOCHEMISTRY (2006)
Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells
A Okamoto et al.
CLINICAL CANCER RESEARCH (2005)
Share Paper
